Chiltern International Ltd. Launches Collaborative Technologies

LONDON, June 10 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), announced the launch of Collaborative Technologies.

“Chiltern’s Collaborative Technologies is a turnkey solution reflecting integrated processes and technology which offers a single access point to clinical study data and the central document repository for the entire study team. Our Data Warehousing brings together data from core clinical systems to present one consolidated view of information,” stated Dr Jim Esinhart, Chiltern Executive Vice President, Global Biometrics and North America.

Glenn Kerkhof, Chiltern CEO, commented, “A key benefit of Collaborative Technologies is the immediate access to current study information which the entire study team can access wherever they are located globally. This means faster decisions can be made on the study which results in time and cost savings for our clients.”

Dr Esinhart added, “In addition to the core components in the Collaborative Technologies platform, it has been configured to work with Chiltern’s proprietary systems such as Chiltern Insight, our clinical trial management system, and Chiltern Safe, our Trial Master File and Electronic Records Management system. We are extremely pleased to report that Collaborative Technologies works hand-in-hand with our industry’s leading systems such as Medidata Rave® and Clinphone Datalabs® for Electronic Data Capture (EDC), Phase Forward’s Empirica Trace for adverse event management and endpoint’s PULSE for Interactive Response Technology (IRT). To summarize, Collaborative Technologies offers our clients a suite of best-in-class technological solutions for their clinical trial needs under one organization.”

Company profile

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern has conducted trials in more than 40 countries, has 24 offices and legal entities within 20 countries, resources in 37 countries and employs nearly 1,400 people globally. Chiltern provides Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions services. Further information: www.chiltern.com.

SOURCE Chiltern